^
    24h
    Trial Combining Pembrolizumab and Cesium 131 Brachytherapy With Salvage Surgery in HNSCC (clinicaltrials.gov)
    P1/2, N=50, Active, not recruiting, University of Cincinnati | Trial completion date: Sep 2025 --> Sep 2026
    Trial completion date
    |
    Keytruda (pembrolizumab)
    1d
    Laryngeal leiomyosarcoma: A rare case report and literature review. (PubMed, Oncotarget)
    This report, representing the first documented case of LLMS from Central Asia, contributes to the limited global experience with this rare tumor. Our review identified four additional LLMS cases published between 2021 and 2024, totaling five recent reports including the present case. Collectively, these demonstrate persistent male predominance, glottic and supraglottic predilection, and survival outcomes consistent with previous observations. Complete surgical excision remains the cornerstone of therapy, while multidisciplinary-guided adjuvant treatment may benefit selected high-grade or high-risk patients. Continued accumulation and molecular characterization of cases are needed to refine prognostic assessment and optimize management strategies.
    Journal
    |
    VIM (Vimentin)
    |
    doxorubicin hydrochloride • ifosfamide
    1d
    Rapamycin Targets Cancer Stem Cells to Decrease Cisplatin Resistance in a Head and Neck Cancer Mouse Xenograft Model. (PubMed, J Oral Pathol Med)
    These findings suggest that rapamycin enhances the mechanistic efficacy of cisplatin by specifically targeting and reducing cisplatin-induced stemness (CD133+ CSC population). This study proposes a viable combination therapy for HNSCC involving an mTOR inhibitor and a platinum-based drug to overcome CSC-mediated resistance.
    Preclinical • Journal
    |
    ALDH1A1 (Aldehyde Dehydrogenase 1 Family Member A1)
    |
    cisplatin • sirolimus
    1d
    A Single-Arm Clinical Study of Autologous Tumor-Infiltrating Lymphocyte Injection (GT307) in the Treatment of Metastatic and Recurrent Advanced Solid Tumors (clinicaltrials.gov)
    P=N/A, N=0, Withdrawn, Grit Biotechnology | N=16 --> 0 | Not yet recruiting --> Withdrawn
    Enrollment change • Trial withdrawal
    1d
    Comparing Intraoperative Indocyanine Green Fluorescence Imaging With Standard Clinical Assessment for Flap Perfusion in Head and Neck Reconstruction (VISION Trial) (clinicaltrials.gov)
    P4, N=244, Not yet recruiting, Region Skane
    New P4 trial
    1d
    LANDMARC: LANDscape MApping of Epitopes and T Cell Receptors for Selected Cancers (clinicaltrials.gov)
    P=N/A, N=105, Recruiting, University Health Network, Toronto | Trial completion date: Feb 2026 --> Feb 2027 | Trial primary completion date: Feb 2026 --> Feb 2027
    Trial completion date • Trial primary completion date
    |
    AFP (Alpha-fetoprotein)
    1d
    REPROton-HN: Prospective Observational Study on Proton Re-irradiation for Locoregional Recurrences of Head and Neck Tumors (clinicaltrials.gov)
    P=N/A, N=50, Recruiting, Istituto Clinico Humanitas
    New trial
    1d
    A Feasibility Study of AI-Assisted Physiotherapy for Oral Cancer Patients (clinicaltrials.gov)
    P=N/A, N=15, Not yet recruiting, National Taiwan University Hospital
    New trial
    2d
    Evaluating a Decreased Dose of Radiation Therapy to the Elective Neck for the Treatment of HPV-Related Oropharyngeal Cancer, ENLIGHT Trial (clinicaltrials.gov)
    P2, N=100, Recruiting, Northwestern University | Not yet recruiting --> Recruiting | Initiation date: Mar 2026 --> Dec 2025
    Enrollment open • Trial initiation date
    2d
    CPI: Pharmacokinetic Study of Pembrolizumab and Its Impact on Immunity and the Tumor Microenvironment, Which May Explain the Efficacy of Post-immunotherapy Chemotherapy. (clinicaltrials.gov)
    P4, N=110, Not yet recruiting, Centre Antoine Lacassagne
    New P4 trial
    |
    Keytruda (pembrolizumab)
    2d
    Integrative multi-omics analysis-based Mendelian randomization identifies association of DNA repair-related genes with oral cancer. (PubMed, Cancer Biomark)
    Multi-omics and tissue analyses identified VHL as the most consistent risk gene, supported by colocalization, TCGA HNSC transcriptomic validation (P < 0.01), and DepMap functional data. GEN1 and POU5F1 expression in salivary gland tissue also associated with OCC risk.ConclusionThis multilayer SMR study reveals causal links between DNA repair-related genes and OCC, highlighting VHL as a key driver and suggesting targets for early detection and precision therapy.
    Journal
    |
    POU5F1 (POU Class 5 Homeobox 1) • HNRNPAB (Heterogeneous Nuclear Ribonucleoprotein A/B) • TP73 (Tumor Protein P73) • GEN1 (GEN1 Holliday junction 5' flap endonuclease)
    |
    POU5F1 expression
    2d
    Clinical efficacy and immunological aspects of neoadjuvant and perioperative therapy in resectable head and neck carcinoma. (PubMed, Cancer Treat Rev)
    Recent phase III data have led to approval of perioperative pembrolizumab for patients with PD-L1-positive (CPS ≥ 1)...In addition, potential strategies to optimize treatment efficacy and to overcome resistance mechanisms of CPI therapy are discussed. Further trials are needed to define optimal treatment protocols, determinate the best timing of surgery, and identify reliable biomarkers for patient selection, to guide evidence-based therapeutic decision-making in routine clinical practice.
    Review • Journal • PD(L)-1 Biomarker • IO biomarker
    |
    PD-L1 (Programmed death ligand 1)
    |
    PD-L1 expression
    |
    Keytruda (pembrolizumab)